抑制核苷酸焦磷酸酶/磷酸二酯酶1:开发焦磷酸钙沉积病改善药物的意义
本研究从骨关节炎(OA)患者关节置换术中获取软骨组织、软骨细胞及软骨来源基质囊泡(MVs),评估新型eNPP1特异性抑制剂SK4A对核苷酸焦磷酸酶活性的影响。结果显示SK4A对软骨细胞无毒性,在培养基和人血浆中稳定,能有效抑制全软骨组织、软骨细胞及MVs中的核苷酸焦磷酸酶活性,并减少ATP诱导的焦磷酸钙沉积(CPPD)。作者认为核苷酸类似物如SK4A或可开发为eNPP1强效特异性抑制剂,用于降低人软骨细胞外焦磷酸水平,以预防和治疗CPPD病。
要点
- OA软骨细胞早期传代表达eNPP1,但进一步传代后表达丢失;核苷酸焦磷酸酶活性也仅在早期传代软骨细胞中检出。
- SK4A对软骨细胞无毒性,在培养基和人血浆中稳定。
- SK4A抑制全软骨组织、软骨细胞及软骨来源MVs的核苷酸焦磷酸酶活性,并减少ATP诱导的CPPD。
核心结论
- 核苷酸类似物如SK4A或可开发为eNPP1强效特异性抑制剂,用于降低人软骨细胞外焦磷酸水平,以预防和治疗CPPD病。
研究设计与样本
- 研究获取骨关节炎(OA)供者行关节置换术的软骨组织、软骨细胞及软骨来源基质囊泡(MVs),评估SK4A对细胞活力的影响(XTT法)、eNPP1表达(western blot)、核苷酸焦磷酸酶活性(比色法及HPLC分析ATP水平)以及ATP诱导的软骨细胞钙沉积(茜素红S染色)。
主要发现
- OA软骨细胞早期传代表达eNPP1,但进一步传代后表达丢失;核苷酸焦磷酸酶活性仅在早期传代软骨细胞中检出。
- SK4A对软骨细胞无毒性,在培养基和人血浆中稳定。
- SK4A有效抑制全软骨组织、软骨细胞及软骨来源MVs中的核苷酸焦磷酸酶活性,并减少ATP诱导的CPPD。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Calcium pyrophosphate deposition (CPPD) is associated with osteoarthritis and is the cause of a common inflammatory articular disease. Ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (eNPP1) is the major ecto-pyrophosphatase in chondrocytes and cartilage-derived matrix vesicles (MVs). Thus, eNPP1 is a principle contributor to extracellular pyrophosphate levels and a potential target for interventions aimed at preventing CPPD. Recently, we synthesized and described a novel eNPP1-specific inhibitor, SK4A, and we set out to evaluate whether this inhibitor attenuates nucleotide pyrophosphatase activity in human OA cartilage. METHODS: Cartilage tissue, chondrocytes and cartilage-derived MVs were obtained from donors with OA undergoing arthroplasty. The effect of SK4A on cell viability was assayed by the XTT method. eNPP1 expression was evaluated by western blot. Nucleotide pyrophosphatase activity was measured by a colorimetric assay and by HPLC analysis of adenosine triphosphate (ATP) levels. ATP-induced calcium deposition in cultured chondrocytes was visualized and quantified with Alizarin red S staining. RESULTS: OA chondrocytes expressed eNPP1 in early passages, but this expression was subsequently lost upon further passaging. Similarly, significant nucleotide pyrophosphatase activity was only detected in early-passage chondrocytes. The eNPP1 inhibitor, SK4A, was not toxic to chondrocytes and stable in culture medium and human plasma. SK4A effectively inhibited nucleotide pyrophosphatase activity in whole cartilage tissue, in chondrocytes and in cartilage-derived MVs and reduced ATP-induced CPPD. CONCLUSION: Nucleotide analogues such as SK4A may be developed as potent and specific inhibitors of eNPP1 for the purpose of lowering extracellular pyrophosphate levels in human cartilage with the aim of preventing and treating CPPD disease.
引用
- Danino O, Svetitsky S, Kenigsberg S, et al. Inhibition of nucleotide pyrophosphatase/phosphodiesterase 1: implications for developing a calcium pyrophosphate deposition disease modifying drug. Rheumatology (Oxford). 2018. PMID: 29688536. doi:10.1093/rheumatology/key092
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。